# Shanghai Beitongji Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-beitongji-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.bio-engine.com
- Total disclosed funding: $90M
- Latest round: Series C (May 15, 2023)
- Investors on record: 11

## About

Established in 2014 and based in Shanghai, China, Shanghai Bioengine Technology is a biotech company that focuses on the development and production of biopharmaceutical products. The firm has over 200 partners, including CSPC, BGI, Boan Biotech, etc. As of 2023, it has 108 employees. In 2015, the company launched a serum-free medium for MDCK cells. In 2016, the company built its Zhangjiang base. In 2017, the company launched a low serum medium for BHK cells. In 2021, the Phase II culture media production base commenced full operation. In May 2023, it raised more than CNY 200 million in series C funding.

The company engages in the development of animal cell culture media. BioEngine has developed nearly 100 types of serum-free media for different cell lines,  including Eden series serum-free medium for CHO cells, HIPP series serum-free medium for immune effector cells for cell therapy, serum-free medium for vaccine production of Vero, etc, which are suitable for antibodies, vaccines, and cell and gene therapy (CGT) fields. BioEngine has supported more than 80 clinical projects in the biopharma industry and has provided nearly 100 cell culture technology services. It provides one-stop services from cell culture process development and optimization, and medium formulation design to medium processing and manufacturing for biopharmaceutical companies and organizations.

The company will use series C funding to accelerate the research and innovation of basic soil for serum-free cultivation, industrial service capabilities, and information construction.

## Funding rounds

- Series C, May 15, 2023, $43M — Legend Capital, Addor Capital, Leo Group, Riverhead Capital, Kington Capital, Xiamen C&D Emerging Industry Equity Investment, Tsing Song Capital, HM Capital, NRL Capital
- Series B, Mar 29, 2022, $31M — Legend Capital, Addor Capital, Tsing Song Capital, Hankang Capital
- Series B, Jul 6, 2021, $15M — Oriental Fortune Capital, Hankang Capital
- Series B, Aug 27, 2019 — Oriental Fortune Capital

## Investors

- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series B
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series B
- Legend Capital — Series B, Series C
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B, Series C
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series B, Series C
- Leo Group — Series C
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series C
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series C
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series C
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series C
- NRL Capital (https://capitalatlas.ai/funds/nrl-capital) — Series C